LncRNA ZEB1 antisense 1 (ZEB1‐AS1), a noncoding antisense transcript controlled by the ZEB1 promoter, serves as biomarker for poor clinical prognosis in patients with GBM and augments cell invasion by inducing EMT activator ZEB1 (Lv et al., 2016). The gene discussed is ZEB1; the disease is glioblastoma.